Friday, November 20, 2026

ImmunoGen Stock Is 32% Up In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

ImmunoGen Stock Is 32% Up In The Last 21 Sessions

(VIANEWS) - Shares of ImmunoGen (NASDAQ: IMGN) rose by a staggering 32.12% in 21 sessions from $13.48 at 2023-05-11, to $17.81 at 17:21 EST on Monday, after two consecutive sessions in a row of gains. NASDAQ is rising 1.53% to $13,461.92, after two successive sessions in a row of gains.

ImmunoGen's last close was $17.16, 1.04% below its 52-week high of $17.34.

About ImmunoGen

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-1.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -111.95%.

Sales Growth

ImmunoGen's sales growth is 218.2% for the ongoing quarter and 309.5% for the next.

More news about ImmunoGen (IMGN).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 12 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.